Biocept., a commercial provider of clinically actionable liquid biopsy tests for cancer patients, said it will work with the Addario Lung Cancer Medical Institute (ALCMI) on a clinical collaboration and initiation of the landmark ALCMI-009 liquid biopsy clinical trial, Biocept said in a press release.
The ALCMI-009 liquid biopsy trial will be conducted by ALCMI and its group of oncology centers in the U.S. and internationally.
The study, which will involve 400 patients, will use Biocept's Target Selector assay platform to help detect and assess cancer biomarkers found in circulating tumor cells and circulating tumor DNA in the lung cancer patient’s blood, Biocept said.
Three goals of the clinical trial include predicting treatment failure prior to progression observance via radiographic imaging, illustrating drug response and identifying resistance mechanisms, Biocept said.
"We are pleased to join forces with major research institutions and cutting-edge molecular diagnostics companies such as Biocept to conduct a large-scale trial evaluating the use of liquid biopsy to detect and monitor key lung cancer biomarkers," Steven Young, ALCMI's president and chief operations officer, said in the release.
The research effort will certainly benefit lung cancer patients, Bonnie Addario, lung cancer survivor and the founder of the Bonnie J. Addario Lung Cancer Foundation and ALCMI, said in the release.
